MENLO PARK, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN) will announce its financial results for the fourth quarter and year ended December 31, 2010 on Thursday, February 24, 2011, after the closing of the equity market. David L. Greenwood, Geron’s President and Chief Executive Officer, will host a conference call for analysts and investors on Friday, February 25, 2011 at 8:00 a.m. Pacific Time, 11:00 a.m. Eastern Time.
Participants can access the conference call live via telephone by dialing 800-322-5044 (U.S.); 617-614-4927 (international). The passcode is 46409714. A live audio-only webcast is also available at http://phx.corporate-ir.net/playerlink.zhtml?c=67323&s=wm&e=3766909. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through March 25, 2011.
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a compound designed to penetrate the blood-brain barrier. The company is developing cell therapy products from differentiated human embryonic stem cells for multiple indications, including central nervous system (CNS) disorders, heart failure, diabetes and osteoarthritis, and has initiated a Phase 1 clinical trial in spinal cord injury. For more information, visit www.geron.com.
Investor and Media Relations
Anna Krassowska, Ph.D., 650-473-7765
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Stem Cells Health Biotechnology Clinical Trials Oncology Pharmaceutical